Mazen Al Mushref, MD
Endocrinology, Diabetes & Metabolism · Grosse Pointe Woods, MINPI 1356781256
Payments from drug & device makers
Across 72 payments — averaging $20.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$355
- Xeris Pharmaceuticals, Inc.$221
- Lilly USA, LLC$127
- Sanofi-aventis U.S. LLC$113
- Medtronic$107
- Mannkind Corporation$90
- plus $458 from 16 others
What the payments were for
- Food & beverage$1,40896%
- Education$624%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 23 | $355 |
| Xeris Pharmaceuticals, Inc. | 11 | $221 |
| Lilly USA, LLC | 7 | $127 |
| Sanofi-aventis U.S. LLC | 5 | $113 |
| Medtronic | 1 | $107 |
| Mannkind Corporation | 3 | $90 |
| BETA Bionics, Inc. | 2 | $49 |
| Novo Nordisk | 2 | $44 |
| Neurocrine Biosciences, Inc. | 2 | $44 |
| Tolmar, Inc. | 2 | $39 |
| Azurity Pharmaceuticals, Inc. | 2 | $38 |
| Radius Health, Inc. | 2 | $34 |
| Rhythm Pharmaceuticals, Inc. | 1 | $29 |
| AstraZeneca | 1 | $28 |
| Dexcom, Inc. | 1 | $22 |
| Boehringer Ingelheim | 1 | $20 |
| Pfizer | 1 | $20 |
| GSK | 1 | $20 |
| Amneal Pharmaceuticals LLC | 1 | $19 |
| Alvogen Inc | 1 | $19 |
| Aimmune Therapeutics, Inc. | 1 | $18 |
| Amryt Pharma Holdings Ltd | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,470 in reported general payments places this provider in the 45th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
See all endocrinology, diabetes & metabolism providers in Michigan →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 86 | $95,930 |
| TrulicityDulaglutide | 65 | $74,037 |
| OzempicSemaglutide | 50 | $70,146 |
| MounjaroTirzepatide | 31 | $35,306 |
| Humalog Kwikpen U-200Insulin Lispro | 13 | $22,704 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $15,135 |
| Novolog FlexpenInsulin Aspart | 45 | $11,678 |
| Humalog Kwikpen U-100Insulin Lispro | 29 | $11,338 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 51 | $8,693 |
| Novolin 70-30 FlexpenInsulin Nph Hum/Reg Insulin Hm | 13 | $3,552 |
| Humulin 70/30 KwikpenInsulin Nph Hum/Reg Insulin Hm | 13 | $2,967 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 23 | $2,108 |
| Hydrocortisone | 43 | $1,887 |
| Repaglinide | 33 | $1,466 |
| Methimazole | 60 | $1,076 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $127 | $109,34396 claims |
| Boehringer IngelheimJardiance | $20 | $95,93086 claims |
| Novo NordiskOzempic | $44 | $70,14650 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $19 | $83883 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
Other endocrinology, diabetes & metabolism in Grosse Pointe Woods
- Tobias ElseAnn Arbor$3.5M
- Elif OralAnn Arbor$2.9M
- Jamal HammoudFlint$2.6M
- Lowell SchmeltzFarmington Hills$2.3M
- George GrunbergerBloomfield Hills$1.9M
- Richard AuchusAnn Arbor$1.3M
- Ariel BarkanAnn Arbor$553K
- Gary EdelsonFarmington Hills$503K
- Michael BrennanSaint Clair Shores$433K
- Abdulsalam Al KassabRochester Hills$351K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.